30results about How to "Inhibition of proliferative activity" patented technology

The invention discloses an application of a cell cycle regulation gene fam114a2. A result of researches shows that the gene has a cell cycle regulating effect, and can inhibit cell proliferation, so the gene can be used as a cell cycle regulating reagent, and can be used as a tumor treatment target gene; and the gene is specifically highly-expressed in kidney cancer, liver cancer, stomach cancer and para-carcinoma tissues, so the gene can be used as a kidney cancer, liver cancer and stomach cancer diagnosis marker, and is of great significance to diagnosing and treating tumors.

The invention relates to the field of medicines, in particular to a polypeptide with the functions of promoting plasminogen to be hydrolyzed into angiostatin and treating malignant tumors. A sequence of the plasminogen polypeptide is THELGHLSQKLYGKRSN and is a bran-new sequence. The plasminogen polypeptide is capable of promoting the hydrolysis of the plasminogen in vitro, inhibiting proliferation of vascular endothelial cells, and improving the survival rate of tumor-bearing mice in an in vivo test, and has potential new medicine development value.

The invention discloses fibroblast growth factor inhibitory polypeptide and an application thereof, and relates to the field of drugs, in particular to the polypeptide capable of restraining fibroblast growth factors and treating malignant tumors. The sequence is PSHNPEEQLSWGDSGEDSEPLP which is a branch-new sequence. The inhibitory polypeptide can restrain the proliferation of colonic cancer cells and hepatoma cells in vitro, the survival rate of tumor-bearing mice can be increased in vivo tests, and potential development value of new drugs can be achieved.

The invention provides application of a small interfering RNA in preparing a medicament for treating colon cancer, wherein the small interfering RNA can inhibit the proliferation activity of colon cancer cells, retard the growth cycle of the colon cancer cells, induce the apoptosis of the colon cancer cells, and lower the activity of an mTOR / p70S6K / 4EBP1 signal channel of the colon cancer; besides, the small interfering RNA has therapeutic action on the transplantable tumor of nude mice colon cancer, and solves the technical problem that the prior art has poor curative effect and patient prognosis by adopting chemotherapy to treat middle and advanced stage colon cancer.

The invention relates to the field of drugs and concretely relates to a polypeptide having the activity of stimulating IL-2-induced T cell kinase and a function of treating cancers. The polypeptide has a novel sequence, can inhibit colon cancer cells and pancreatic cancer cell proliferation activity, and can inhibit the migration of vascular endothelial cells. An in-vivo test proves that the polypeptide improves a survival rate of tumor-bearing mice and has a potential novel drug development value.

The invention relates to the field of biomedicine, in particular to the application of E3 ubiquitin ligase ASB3 as a new anti-tumor target in the preparation of drugs for treating liver cancer. The invention provides a new treatment method for liver cancer by specifically down-regulating ASB3 with small interfering RNA. Interfering with ASB3 can inhibit the proliferation of liver cancer cells and induce apoptosis of liver cancer cells; it has a therapeutic effect on subcutaneous liver cancer implantation in nude mice; it solves the technical problems of poor curative effect and poor prognosis of the existing treatment methods for middle and advanced liver cancer.

The invention relates to the field of medicine, and particularly relates to a polypeptide which is capable of promoting activity of perforin and treating malignant tumor. Sequences of the polypeptide are brand new sequences, are capable of inhibiting proliferation activities of a hepatoma carcinoma cell and a liver cancer stem cell simultaneously at the same time, and can promote apoptosis of the liver cancer stem cell. In an in-vivo test, a survival rate of a nude mouse bearing the liver cancer and the tumor is improved, and thus the perforin chaperonin polypeptide has potential new drug development value.

The invention discloses a pharmaceutical composition containing medicinal calcium salt for early preventing colorectal adenoma or colorectal cancer. The pharmaceutical composition contains sodium butyrate and medicinal calcium salt, wherein the mass ratio of the sodium butyrate to elemental calcium in the pharmaceutical composition is (2.47-4.95):1. The pharmaceutical composition disclosed by theinvention can reduce cancer genes related to the colorectal cancer and can increase related cancer suppressor genes and signal passages to suppress colorectal cancer cell proliferation and migration capabilities and retard cell growth cycle, thereby achieving the purposes of suppressing the occurrence of the colorectal cancer, lowering the incidence rate of the colorectal cancer of mice, and reducing the tumor volume.

The invention relates to the field of medicines, particularly polypeptides which can be used for inhibiting a vascular endothelial growth factor C and treat acute lymphocytic leukemia. The sequence of the polypeptides is DFMCQCVCNKLFRRP which is a brand new sequence; the polypeptides can be used for in vitro inhibiting the vascular endothelial growth factor C at a one-micromole level and moreover improving the survival rate of tumor-bearing mice in an in vivo test and have a potential new drug development value.

The invention relates to the field of medicines and in particular relates to a polypeptide capable of activating angiostain and treating malignant tumour. A sequence of the polypeptide is EALALMYYHSQSLRKTYP is brand-new, and the polypeptide can activate angiostain in vitro and inhibit proliferation of vascular endothelial cells and also can improve survival rate of tumour-bearing mice during in-vivo test, so that the polypeptide has potential value in development of new drugs.

The invention discloses application of pectolinarin in preparation of an anti-osteosarcoma medicine and an anti-osteosarcoma medicine preparation, and belongs to the technical field of medicines. In-vivo and in-vitro experiments prove that the pectolinarin can inhibit growth and proliferation of various osteosarcoma cells, can promote apoptosis of the osteosarcoma cells, can intervene the cell cycle, can retard the cells in the G1 stage, can reduce the number of the cells in the G2 stage and can inhibit the cell division ability; the invasion and migration of HOS and 143B osteosarcoma cells can be inhibited; and animal experiments prove that pectolinarin can obviously inhibit the volume of nude mouse subcutaneous 143B cytoma and can well inhibit the growth of osteosarcoma. The pectolinarin is expected to become a medicine for treating osteosarcoma and has a wide prospect in the aspect of development of the medicine for treating osteosarcoma.

The invention discloses the application of the cell cycle regulating gene fam114a2. It is found through research that the gene has a cell cycle regulating effect and inhibits cell proliferation, so it can be used as a cell cycle regulating agent and as a target gene for tumor treatment; and the gene is used in renal cancer , liver cancer, gastric cancer and paracancerous tissues are specifically highly expressed, so it can also be used as a diagnostic marker for renal cancer, liver cancer, and gastric cancer, and is of great significance to the diagnosis and treatment of tumors.